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The key issues in the successful management of malaria are early 
and accurate diagnosis and urgent treatment with effective drugs. 
Disease presentation is, however, not specific – progression 
to complicated disease may be rapid in non-immune persons, 
particularly in young children and pregnant women, and parasite 
drug resistance significantly influences treatment outcome.1
There are four species of human malaria parasite, but this 
brief review focuses on the most prevalent and pathogenic 
species, Plasmodium falciparum.  The outcome of a falciparum 
malaria attack depends on the interaction of host, parasite and 
environmental factors, and ranges from asymptomatic or mildly 
symptomatic disease, through severe, complicated malaria, to 
death. Severe or fatal malaria is almost invariably caused by P. 
falciparum. This reflects the ability that the falciparum parasite 
has evolved for attachment (cytoadherence) of the schizont-
infected erythrocyte to the capillary walls of the brain and other 
organs.  Through various mechanisms, the end results are organ 
dysfunction, damage or failure, which are reflected in the severe 
and complicated forms of malaria.1
Presentation and diagnosis  
The prompt and accurate diagnosis of malaria is critically 
important because of the potential for rapid clinical progression 
to complicated and possibly fatal disease.  Three components 
contribute to an optimal diagnostic outcome: 
•    a high index of suspicion in travellers to or residents in malaria 
transmission areas and their health care providers, who should 
take an adequate travel history in any person with fever or flu-
like illness 
•    clinical astuteness and experience, and
•    diagnostic tests. 
The presentation of malaria is highly variable and mimics many 
other diseases, most commonly influenza, but also bacterial 
septicaemia, East African trypanosomiasis, meningitis, typhoid 
fever, tick bite fever, viral haemorrhagic fever and viral hepatitis. 
Paroxysms of fever and rigors are typical in adults. Some of the 
following symptoms may occur: headache, tiredness, myalgia, 
abdominal pain, diarrhoea, loss of appetite, nausea and vomiting, 
and cough. In young children malaria may present with fever, 
lethargy, poor feeding, vomiting, diarrhoea and cough. Malaria 
is frequently missed or misdiagnosed in pregnancy and needs 
to be differentiated from complications of pregnancy including 
intrauterine sepsis and pyelonephritis, as signs and symptoms may 
be similar, notably abdominal pain and fever.2,3
Examination of patients with suspected malaria may reveal minimal 
physical signs. The presence of fever or a history of fever in the 
previous 3 days is usual, but does not invariably occur. An enlarged 
spleen is uncommon in areas of low-intensity malaria transmission; 
therefore the absence of splenomegaly does not exclude malaria. 
Management of uncomplicated malaria
Early diagnosis and treatment is the key to effectively managing  
malaria.
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Uncomplic ated malaria
The patient should be carefully examined 
for complications of malaria, such as shock, 
altered level of consciousness, jaundice, 
anaemia, and respiratory distress, including 
acidotic-type respiration and bleeding. The 
presence, on examination, of another disease 
does not necessarily exclude malaria, and 
both diseases would need to be investigated 
and managed. The health practitioner should 
be warned against attributing fever to the 
presence of minor respiratory infections, 
e.g. pharyngitis, in patients who have been 
exposed to malaria.  Likewise, malaria is often 
missed in patients with co-morbid disease 
because signs and symptoms are attributed 
to the underlying disease, even when there 
is a history of malaria exposure.2,3
Malaria transmission very rarely occurs 
outside malaria transmission areas – in the 
form of Odyssean or airport malaria, or 
needle and transfusion malaria. Therefore 
it is prudent that, when there is no other 
obvious cause of fever, malaria should still 
be excluded,4 even if a recent history of 
visiting or living in a malaria area is not 
forthcoming.
Laboratory testing for parasites should 
be done and results obtained urgently 
in all patients with a clinical suspicion 
of malaria, irrespective of the season or 
whether the patient has/has not taken 
chemoprophylaxis.
Microscopy of thick blood smears stained 
with Giemsa remains the mainstay of 
diagnosis. This requires skill and experience 
that is not always available. Examination of 
a thin blood smear will give an indication 
of the parasite species and density of 
parasitaemia, both of which will influence 
treatment.5
Rapid diagnostic tests (see article by Dini 
and Bell),  based on lateral-flow immuno-
chromatographic (dipstick) detection of 
malaria antigens, are suitable for use by 
persons without specific laboratory training. 
Most commercially available tests detect 
the P. falciparum histidine-rich protein 2 
(PfHRP-2) antigen. As HRP-2 persists after 
successful treatment rapid tests are used only 
for initial diagnosis of malaria and cannot 
be used to monitor treatment response. 
Parasite density cannot be quantified with 
rapid diagnostic tests.6,7
Alternative techniques, such as acridine 
orange (AO) staining and the quantitative 
buffy coat (QBC) method, have high 
sensitivity but may be associated with 
problems of interpretation and species 
identification.  
A negative test does not exclude the diagnosis 
and repeat testing within 8 - 24 hours, without 
attempting to coincide with fever peak timing, 
is mandatory until a positive result is reported 
or an alternative definitive diagnosis is made. 
Prophylaxis and antibiotic use may prolong 
incubation periods and suppress malaria 
parasite densities below detectable levels.5
In the absence of, or if there is a delay 
in obtaining, a definitive parasitological 
diagnosis patients with severe malaria, or at 
high risk thereof, should be presumptively 
treated for malaria on clinical grounds.
Thrombocytopenia is a common finding in 
patients with malaria. A blood smear should 
be checked for malaria parasites whenever 
this laboratory finding is made unexpectedly.
Assessment of disease 
severity3,8
Uncomplicated malaria is defined as 
symptomatic malaria without signs 
of severity or evidence of vital organ 
dysfunction. In acute falciparum malaria 
there is a continuum from mild to severe 
malaria. Young children, pregnant women 
and non-immune adults with malaria may 
deteriorate particularly rapidly. The common 
tendency is to underestimate the severity of 
disease. The risks of under-treating severe 
malaria considerably exceed those of giving 
parenteral treatment to a patient who does 
not need it. The presence of one or more of 
the clinical or laboratory features listed in 
Table I classifies the patient as suffering from 
severe malaria. The presence of acidosis is 
a particularly accurate predictor of poor 
outcome.  
The choice of treatment depends on 
disease severity, malaria species, patient 
characteristics (pregnancy, extremes of 
age, co-morbidity, allergies, concurrent 
medication) and presence of vomiting.
Treating uncomplicated falciparum 
malaria3.8
The objective of treating uncomplicated 
malaria is to eradicate the Plasmodium 
parasite,  prevent progression to severe 
malaria, and prevent additional morbidity 
associated with treatment failure. From a 
community perspective the goals are to 
reduce malaria transmission and to prevent 
the emergence and spread of antimalarial 
resistance. To achieve these objectives the 
WHO now recommends treatment with 
artemisinin-based combinations (ACTs).9 
Evidence of their superiority compared 
with monotherapies has been clearly 
documented.8 Artemether-lumefantrine (AL, 
Coartem) is the first ACT to be registered in 
South Africa and has been the standard drug 
for the treatment of uncomplicated malaria 
in KwaZulu-Natal since 2001, Limpopo 
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Table I. Clinical and laboratory criteria for severe malaria
Clinical
Impaired consciousness, multiple convulsions
Respiratory distress, acidotic breathing, pulmonary oedema
Circulatory collapse
Jaundice
Bleeding
Prostration
Laboratory
Hypoglycaemia (blood glucose <2.2 mmol/l)
Acidosis (plasma bicarbonate <15 mmol/l or serum lactate >5 mmol/l)   
Hepatic transaminases >3 times normal
Renal impairment (serum creatinine >265 µmol/l or rapidly rising creatinine or urine 
output <400 ml/day in an adult)
Haemoglobin <5 g/l
Parasitaemia ≥5%
≥ 5% neutrophils contain malaria pigment
Presence of schizonts of P. falciparum in peripheral blood smear
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since 2004, and Mpumalanga since 2005. 
AL had a cure rate of 99%,10  and is now 
recommended nationally for the treatment 
of uncomplicated malaria.3
AL is available as co-formulated tablets 
containing 20 mg of artemether and 120 mg 
of lumefantrine. The total recommended AL 
treatment is a 6-dose regimen given twice 
daily over 3 days (Table II). Treatment should 
preferably be dosed according to body 
weight rather than age.  An advantage of this 
particular combination is that lumefantrine 
is not available as a monotherapy and has 
never been used by itself for the treatment 
of malaria. Lumefantrine absorption is 
enhanced by co-administration of fat. Low 
drug levels, and the resultant treatment 
failure, could result from inadequate fat 
intake. It is therefore essential that patients 
or caregivers are informed of the need to take 
AL with milk or fat-containing food (1.2 g of 
fat, equivalent to 100 ml milk) – particularly 
on the second and third days of treatment.11
Oral quinine for 7 days, combined with 
either doxycycline or clindamycin, remains 
an alternative to AL, but compliance with 
this poorly tolerated regimen is seldom 
achieved in an outpatient setting. 
Ideally, treatment should be initiated in 
hospital, as disease severity is frequently 
underestimated and progression to severe 
malaria in non-immune individuals can 
occur despite treatment. The clinical and 
parasitological response of patients to 
treatment, particularly their mental state, 
respiratory rate and urine output, should be 
monitored regularly and carefully. If hospital 
admission is not feasible, patients should at 
least be observed for 1 hour after treatment 
to ensure that the medication is absorbed 
and not vomited. Patients who cannot 
tolerate oral treatment because of repeated 
vomiting will require parenteral quinine (10 
mg/kg). Adequate (but not excessive) fluids 
should be given, along with paracetamol (15 
mg/kg) and tepid sponging, if required. 
Patients should respond clinically and 
parasitologically to AL within 24 - 48 hours. 
Patient adherence is a major determinant 
of the response to antimalarial therapy; 
therefore patients and caregivers need to 
be given a clear explanation of the times 
of dosing and be adequately motivated to 
complete the treatment regimen even if 
symptoms resolve earlier. Poor compliance 
and possible drug resistance should be 
considered if patients have not improved 
significantly within 72 hours, when rescue 
treatment with quinine may be necessary. 
In the rare event of patients who fail AL 
treatment despite full compliance, a full 
treatment course of oral quinine (plus 
doxycycline or clindamycin) should be 
given under observation in hospital. Limited 
data support the use of the same regimen in 
patients weighing more than 65 kg, although 
this group has been less well studied.
The safety of AL is supported by a reasonable 
evidence base, but mainly from clinical trials 
conducted primarily in South-East Asia.12 
Rare but serious side-effects are often not 
detected in clinical trials. It is essential that 
health care workers report any suspected, 
serious adverse drug reactions, particularly 
to new medicines, to the National Adverse 
Drug Event Monitoring Centre (tel (021) 
406-6234 for an ADR report form). 
Treatments not recommended for 
falciparum malaria
Monotherapies (antimalarial agents used 
on their own) are no longer recommended 
for the treatment of falciparum 
malaria. Chloroquine and sulfadoxine-
pyrimethamine (Fansidar, Roche) are not 
used after the emergence of high-level 
resistance in much of Africa, including 
South Africa. Artemisinin derivatives 
(artemether, artesunate) should not be used 
as monotherapy as these could select for 
drug resistance and compromise the value 
of the ACTs on which we rely heavily for 
effective treatment.8 Compliance with the 7-
day monotherapy regimen required to effect 
a cure is hard to achieve when symptoms are 
generally relieved within 48 hours. Although 
no artemisinin monotherapies are registered 
in South Africa, there is concern with regard 
to the availability of these in neighbouring 
countries and over-the-counter herbal 
and homeopathic preparations. In South 
Africa mefloquine is registered only for 
prophylaxis and not for treatment, given the 
higher incidence of severe neuropsychiatric 
adverse effects associated with treatment 
doses.12 Halofantrine treatment is not 
advisable given the associated cardiotoxicity, 
variable bioavailability and drug 
interactions in patients who have taken 
mefloquine prophylaxis. Clindamycin and 
doxycycline are too slow acting to be used as 
monotherapies, but are used in combination 
with quinine. 
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Table II. Dosing schedule for artemether-lumefantrine
Body weight Age Number of tablets and approximate time of dosing
0 hrs 8 - 12 hrs 24 hrs 36 hrs 48 hrs 60 hrs
5 - 14 kg (<3 yrs)    1        1      1     1     1     1
15 - 24 kg (3 - 8 yrs)    2        2      2     2     2     2
25 - 34 kg (9 - 14  yrs )    3        3      3     3     3     3
35+ kg (>14 yrs )    4        4      4     4     4     4
In a nutshell 
•    Malaria requires urgent diagnosis and 
urgent treatment.
•    It is easy to underestimate disease se-
verity.
•    Uncomplicated malaria may progress 
to severe disease despite recommended 
treatment.
•    Careful monitoring and management of 
complications are critically important. 
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